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Docetaxel (75mgm
 2 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant
toxicity. To verify whether a weekly schedule (33.3mgm
 2 for 6 weeks) improved quality of life (QoL), a phase III study was
performed with 220 advanced NSCLC patients, p75 years, ECOG PS p2. QoL was assessed by EORTC questionnaires and the
Daily Diary Card (DDC). No difference was found in global QoL scores at 3 weeks. Pain, cough and hair loss significantly favoured the
weekly schedule, while diarrhoea was worse. DDC analysis showed that loss of appetite and overall condition were significantly
worse in the 3-week arm in the first week, while nausea and loss of appetite were more severe in the weekly arm in the third week.
Response rate and survival were similar, hazard ratio of death in the weekly arm being 1.04 (95% CI 0.77–1.39). A 3-weekly
docetaxel was more toxic for leukopenia, neutropenia, febrile neutropenia and hair loss; any grade 3–4 haematologic toxicity was
significantly more frequent in the standard arm (25 vs 6%). The weekly schedule could be preferred for patients candidate to receive
docetaxel as second-line treatment for advanced NSCLC, because of some QoL advantages, lower toxicity and no evidence of
strikingly different effect on survival.
British Journal of Cancer (2004) 91, 1996–2004. doi:10.1038/sj.bjc.6602241 www.bjcancer.com
Published online 23 November 2004
& 2004 Cancer Research UK
Keywords: quality of life; docetaxel; weekly schedule; second line; advanced NSCLC
                                                          
Platinum-based chemotherapy is the most common treatment for
patients with advanced non-small-cell lung cancer (NSCLC),
thanks to a small survival advantage found in a metanalysis of
11 randomised trials (Non Small Cell Lung Cancer Collaborative
Group, 1995). Cisplatin or carboplatin are usually administered in
two-drug combinations with paclitaxel, docetaxel, gemcitabine, or
vinorelbine. About one-third of patients achieve clinical remission
and another third temporary disease stabilisation; almost all
patients ultimately suffer progression of the disease and die for
lung cancer.
At the time of disease progression many patients still have a
good performance status and a second-line chemotherapy is a
reasonable therapeutic option. Docetaxel 75mgm
 2 once every 3
weeks prolongs survival compared to best supportive care
(Shepherd et al, 2000) and produces less deterioration of pain
and fatigue (Dancey et al, 2004). However, myelosuppression is
frequent and severe (Fossella et al, 2000; Shepherd et al, 2000).
Weekly scheduling of docetaxel (Hainsworth et al, 1998) might
remarkably reduce myelotoxicity in pretreated NSCLC patients
(Lilenbaum et al, 2001), without decreasing antitumoral activity.
We performed a multicentre randomised clinical trial to compare a
weekly schedule of docetaxel against the standard 3-week regimen
in terms of quality of life (QoL), toxicity and efficacy.
PATIENTS AND METHODS
Patient selection and baseline assessment
Patients, younger than 75 years, were required histological or
cytological proof of NSCLC, stage IV or IIIB with malignant pleural
effusion and/or metastatic supraclavicular lymphnodes, evidence
of progressive disease during or after first-line chemotherapy,
ECOG performance status 0–2, adequate haematology (absolute
neutrophil count X2000mm
 3, platelets X100000mm
 3 and
haemoglobin X10gdl
 1) and biochemistry (serum creatinine
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lp1.25 upper normal limit, SGOT and SGPT and bilirubin
p1.25 upper normal limit, unless due to liver metastases),
availability to complete QoL questionnaires, written informed
consent. Patients with symptomatic brain metastases or prior
invasive malignancies were excluded. The protocol was approved
by ethical committees at each participating institution.
Complete history and physical examination, routine haematol-
ogy and biochemistry, staging with chest radiographs, chest, brain
and abdominal computed tomography (CT), and QoL assessment
were required before randomisation.
Treatment schedules
The control arm included docetaxel 75mgm
 2 on day 1 every 3
weeks for six cycles of chemotherapy; the experimental treatment
was docetaxel 33.3mgm
 2 on days 1, 8, 15, 22, 29, 36 every 8 weeks
(6 weeks of treatment followed by 2 weeks of rest) for two cycles
(i.e. 12 administrations); treatment in both arm could be
suspended in case of progression or unacceptable toxicity. Planned
dose-intensity was the same in both arms (i.e. 25mgm
 2week
 1).
Further therapy was discretional. The following criteria were
required to give chemotherapy: neutrophils X1500ml
 1, platelets
X100000ml
 1, haemoglobin X8gdl
 1 and absence of grade X2
nonhaematologic toxicity (excluding alopecia). Lacking these
conditions, a 1-week delay was planned and treatment was stopped
after two consecutive delays. Dose reductions and prophylactic use
of haemopoietic colony stimulating factors were not allowed.
Docetaxel was given intravenously in 1-h; dexamethasone (8mg
i.m. or i.v.) was given at  12, 0, þ12, þ24 and þ36h of every
docetaxel administration in the standard arm and at  12, 0 and
þ12h in the weekly arm.
Design
Centralised phone randomisation (1:1 ratio) was performed at the
Clinical Trials Unit of the National Cancer Institute of Naples,
using a computer-driven minimisation procedure stratified by
center, performance status (0 vs 1 vs 2), objective response to first-
line chemotherapy (complete or partial response vs stable or
progressive disease) and type of previous treatment (with vs
without platinum).
The primary end point of the study was QoL. Three instruments
were applied.
The EORTC QLQ-C30 explores functional scales (physical, role,
emotional, social and cognitive functioning) symptoms (fatigue,
pain, emesis, dyspnea, insomnia, appetite, diarrhoea, constipa-
tion), financial impact, and global health status (Aaronson et al,
1993). The EORTC QLQ-LC13 assesses lung cancer symptoms
(Bergman et al, 1994). Scores were computed according to EORTC
rules (Fayers et al, 1999). Questionnaires were administered before
randomisation and 3 weeks after beginning of therapy in both
arms; a third questionnaire was administered before the third cycle
in the 3-week arm and before the second cycle in the weekly arm
(Figure 1).
The Daily Diary Card (DDC) was designed by the Medical
Research Council Lung Cancer Working Party (Fayers et al, 1991;
Fayers, 1995) to capture rapid and transient changes of sleeping,
mood, well-being, level of activity, nausea, vomiting, appetite loss
and pain. DDC was collected after 3 and 6 weeks (Figure 1).
Overall survival was defined as the interval from date of
randomisation and date of death or date of last follow-up
information for living patients. Objective response, categorised
according to RECIST (Therasse et al, 2000), was evaluated at the
end of the third and sixth cycles of treatment (approximately 9 and
18 weeks) in the standard arm and after six and 12 administrations
(approximately 8 and 16 weeks) in the experimental arm. The best
response was recorded for each patient and confirmation was not
performed. Patients who stopped treatment because of toxicity or
refusal or death before restaging were defined as nonresponders in
the calculation of response rate. Time to disease progression was
not described nor analysed, because of the bias determined by the
unequal cycle duration in the two treatment arms (Green et al,
2002b).
For toxicity assessment, haematology was repeated weekly and
biochemistry at 3 and 6 weeks in both arms. Toxicity was coded
according to NCI-CTC (National Cancer Institute – Cancer
Therapy Evaluation Program, 1999). The worst degree of toxicity
experienced during the treatment was computed for each patient.
Sample size
Global health status scale (items 29 and 30) of EORTC QLQ-C30
after 3 weeks from the start of chemotherapy was used to plan
sample size. A 90% power to detect an effect size of 50% (i.e. a
difference between mean scores of global health status equal to
50% of the standard deviation) after 3 weeks of chemotherapy was
planned. Such an effect size has been correlated with conditions of
‘moderate’ or ‘very much’ positive changes in a subjective
satisfaction questionnaire (Osoba et al, 1998). With a two-sided
significance level of 0.05, a total of 172 patients were needed
(nQuery Advisor
s 4.0, Statistical Solutions Ltd, Cork, Ireland).
Assuming a 25% dropout rate, 215 patients were required.
Statistical analysis
All the analyses were based on ‘intention-to-treat’. Statistical tests
were limited to QoL data at 3 weeks, because comparison beyond
that time could be biased by different scheduling (Figure 1). With
EORTC questionnaires, differences from baseline scores were
compared by Wilcoxon rank-sum test. QoL response was defined
‘improved’ (3-week score X10 points better than baseline), ‘worse’
(score X10-points worse than baseline), or ‘stable’ in between
(Osoba et al, 1998). Comparisons of QoL response was carried out
with an exact linear rank test. For DDC, the daily rate of patients
falling into the two worst scores was calculated for each item. A
null hypothesis that the effect of treatments did not change across
time was assessed by an interaction test across weeks 1–3
(reported as Pint). The exact Wilcoxon rank-sum test was applied
either on the overall period if there was no statistical interaction
(reported as Poverall), or separately for each week if a significant
interaction was evident (reported as P1, P2, and P3 for weeks 1–3
respectively). All P-values were considered significant if p0.05.
Planned survival analysis required 190 deaths to detect a 50%
improvement of median survival with 80% power, an expected
median survival of 30 weeks in the control arm (Shepherd et al,
2000), two-sided alpha level of 0.05, and one interim analysis. The
latter, carried out with blinded treatment, using the alpha spending
function (Lan and DeMets, 1983), based on O’Brien and Fleming
(1979) sequential group design, did not produce study termination.
Weeks 1
Standard 3-weekly arm
Experimental weekly arm
∗
∗ ∗∗∗
∗
EORTC QoL
Daily diary card
Chemotherapy
EORTC QOL
Chemotherapy
Daily diary card
∗ ∗ ∗ ∗ ∗
23456789
Figure 1 Timing of QoL assessment.
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lSurvival curves were estimated by Kaplan and Meier (1958)
method. Cox (1972) model was applied for multivariable analyses.
The Fisher’s exact test was applied to compare the objective
response rate, defined as the proportion of complete and partial
responses on the whole number of patients. Toxicities were
compared by an exact linear rank test (all grades) and by Fisher’s
exact test (grade 3–4 vs 0–2). East software
s 2.0, 1992, Cytel
Software Corp, Cambridge, MA, USA and StatXact5.0.3, 2001, Cytel
Software Corp., Cambridge, MA, USA were used.
RESULTS
Patient characteristics
In total, 220 patients were randomised, between December 2000
and August 2002; 21 were found ineligible after randomisation
because had not filled in baseline QoL (16 cases), progressed
during adjuvant chemotherapy (two cases) or during second-line
chemotherapy (two cases) and one case because of a previous
bladder neoplasm (Figure 2). Baseline characteristics for the 220
patients (Table 1) were balanced between the two arms. Median
age was 63 years, 83% of patients were male, ECOG performance
status was 0–1 in 84 and 86% of subjects had stage IV disease.
Previous chemotherapy was platinum-based in 85% of the patients.
Chemotherapy
After randomisation, six patients did not receive the assigned
treatment (Figure 2): in the 3-week arm, two refused treatment,
one suffered progression of brain metastases and one had acute
clinical deterioration, before starting chemotherapy; in the weekly
arm, one patient died and one was lost, immediately after
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Assigned 3-weekly docetaxel: 110
Ineligible: 11
Missing baselne QoL: 8
PD during adjuvant CT: 1
3rd line treatment: 1
2nd cancer: 1 (bladder spf)
Did not receive 3-weekly docetaxel: 4
Early deterioration: 2
Refused after randomisation: 2
98 dead; 12 alive
followed 6 months: 3
followed 6−12 months: 1
followed >12 months: 8
Completed baseline QoL: 102
Completed 3-week QoL: 82 
Available for response and survival: 110
Available  for toxicity: 106
Randomised
220
Assigned weekly docetaxel: 110
Ineligible: 10
Missing baseline QoL: 8
PD after adjuvant CT:1 
3rd line treatment:1
Did not receive weekly docetaxel: 2
Lost immediately after randomisation: 1
Dead immediately after randomisation: 1
99 dead; 11 alive 
Followed 6 months: 3
Followed 6−2  months: 2
Followed >12 months: 6
Completed baseline QoL: 102
Completed 3-week QoL: 77 
Available for response and survival: 110
Available  for toxicity: 108
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Figure 2 Study flow according to CONSORT.
Table 1 Baseline characteristics by treatment arm
Variable
3-weekly
(N¼110)
Weekly
(N¼110)
Total
(N¼220)
Age
Median 62 63 63
Range 26–74 28–75 26–75
Sex
Males 88 (80%) 95 (86%) 183 (83%)
Females 22 (20%) 15 (14%) 37 (17%)
Stage
IIIB 21 (19%) 10 (9%) 31 (14%)
IV 89 (81%) 100 (91%) 189 (86%)
Histotype
Squamous/epidermoid 31 (28%) 38 (35%) 69 (31%)
Adenocarcinoma 58 (53%) 50 (45%) 108 (49%)
Large cells 3 (3%) 2 (2%) 5 (2%)
Mixed 3 (3%) 3 (3%) 6 (3%)
Undefined 15 (14%) 17 (15%) 32 (15%)
PS
0 35 (32%) 36 (33%) 71 (32%)
1 58 (53%) 56 (51%) 114 (52%)
2 17 (15%) 18 (16%) 35 (16%)
Previous treatment with platinum
No 16 (15%) 18 (16%) 34 (15%)
Yes 94 (85%) 92 (84%) 186 (85%)
Response to first line chemotherapy
Complete or partial 34 (30%) 36 (32%) 70 (32%)
Stable or progression 76 (70%) 74 (68%) 150 (68%)
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lrandomisation. In the 3-week arm, 69% of patients received at least
half of the planned therapy (three cycles) and 23% completed the
treatment; in the weekly arm 62% received half of the planned
therapy (six administrations) and 25% completed the treatment.
Treatment was stopped because of disease-related causes (pro-
gression or death) in 59.1 and 51.8%, and because of toxicity
or refusal in 10.9 and 20.9% of the patients in the weekly and the
3-weekly arms, respectively.
EORTC questionnaires
In the 3-week arm, out of 102 patients with baseline data, 100 were
alive at 3 weeks and 82 filled in the second questionnaire, while the
third one was completed by 67. In the weekly arm, out of 102
patients with baseline data, 98 were alive at 3 weeks and 77 filled in
the second questionnaire, while the third one was completed by 43.
At 3 weeks there was no statistical difference in compliance
between the two arms (P¼0.20).
Baseline mean scores were similar between the two arms for all
of QoL items (Table 2). Mean changes from baseline of QoL
domains are displayed in Figure 3. Global QoL did not show
significant variations. Functioning scales did not change much
during the first 3 weeks, while varied more evidently at the third
questionnaire; in all cases, scores were consistently better with
weekly docetaxel (dotted bars). For patients in the weekly arm,
statistically significant differences at the second questionnaire
were observed for better pain (P¼0.04) and cough (P¼0.007), less
hair loss (Po0.001) and worse diarrhoea (P¼0.01). QoL response
after 3 weeks showed significant differences only for cough and
hair loss, in favour of patients in the weekly arm (Table 2).
Daily Diary Card
DDC was compiled and delivered by 69 and 61 patients in the 3-
weekly arm and by 70 and 56 in the weekly arm, after 3 and 6 weeks,
respectively. The rates of patients falling into the two worst categories
for each item day by day (Figure 4) show that nausea and vomiting
had negligible impact in both arms, while with weekly treatment loss
of appetite tended to be more evident, and pain was better controlled
during the first 3 weeks. For vomiting, pain, insomnia, mood and
physical activity there was no evidence that the effect of treatments
changed across the time (Pint40.05); for all of these items no
significant differences between arms were observed (Poverall40.05),
except for pain that was constantly lower in the weekly arm
throughout the whole period of observation (Poverall¼0.04). On the
other hand, the interaction test was statistically significant
(Pintp0.05) for nausea, loss of appetite and overall condition,
suggesting that the effect of treatments on QoL changed across
weeks. Indeed, separate comparisons by weeks showed that, in the 3-
week arm, loss of appetite and deterioration of general condition
were worse during the first week (P1¼0.04 for both), while, in the
weekly arm, nausea and loss of appetite were more severe during the
third week (P3¼0.02 and 0.002, respectively).
Efficacy
All 220 randomised patients were included in intention-to-treat
analyses, irrespective of whether they received protocol therapy.
With 197 deaths, 98 in the standard arm and 99 in the experimental
arm, the hazard ratio of death was 1.04 (95% CI 0.77–1.39; P¼0.80)
for patients receiving weekly docetaxel, in a Cox model including
performance status, age, sex, stage, previous cisplatin and response
to first-line treatment as covariates. Overall survival curves are
shown in Figure 5. Median survival was 29 weeks (95% CI 21–36)
and 25 weeks (95% CI 18–34), while 1-year survival probability was
0.21 and 0.31, in the 3-week and weekly arm, respectively. Only
partial responses were observed with an objective response rate of
2.7 and 5.5% in the 3-weekly and weekly arm, respectively (P¼0.50).
Toxicity
Patients who received at least one dose of chemotherapy (N¼214)
were included in toxicity analysis (Table 3). Standard 3-week
docetaxel caused more leukopenia, neutropenia, febrile neutropenia
Table 2 Quality of life analysis
Domain/item
3-weekly docetaxel Weekly docetaxel
P-value
Baseline,
mean (s.d.)
Improved,
N (%)
Stable,
N (%)
Worse,
N (%)
Baseline,
mean (s.d.)
Improved,
N (%)
Stable,
N (%)
Worse,
N (%)
Global QoL 55.2 (21.2) 23 (28) 35 (43) 24 (29) 55.5 (24.8) 16 (21) 42 (55) 19 (25) 0.90
Physical 72.6 (20.7) 11 (14) 50 (62) 20 (25) 69.4 (21.4) 12 (16) 54 (72) 9 (12) 0.09
Role 70.4 (31.1) 21 (27) 33 (42) 25 (32) 64.3 (33.1) 23 (31) 35 (47) 16 (22) 0.26
Emotional 71.0 (19.2) 14 (17) 46 (56) 22 (27) 69.6 (21.6) 17 (22) 47 (61) 13 (17) 0.14
Cognitive 87.7 (17.7) 13 (16) 46 (56) 23 (28) 86.4 (16.9) 16 (21) 48 (62) 13 (17) 0.11
Social 79.6 (23.7) 19 (23) 38 (46) 25 (30) 77.1 (24.1) 21 (28) 40 (53) 15 (20) 0.22
Pain 28.9 (27.4) 23 (28) 36 (44) 22 (27) 30.7 (31.7) 29 (38) 32 (42) 16 (21) 0.20
Appetite loss 15.5 (23.8) 9 (11) 58 (72) 14 (17) 23.5 (27.2) 16 (21) 44 (58) 16 (21) 0.60
Constipation 28.7 (29.8) 23 (28) 48 (59) 10 (12) 21.5 (27.3) 19 (25) 50 (66) 7 (9) 0.93
Financiary 17.8 (28.3) 9 (11) 58 (72) 13 (16) 13.9 (22.2) 9 (12) 59 (78) 8 (11) 0.41
Fatigue 32.9 (20.6) 15 (19) 32 (40) 34 (42) 40.0 (25.9) 19 (25) 29 (38) 29 (38) 0.42
Nausea/vomiting 6.1 (14.3) 13 (16) 58 (72) 10 (12) 7.7 (16.4) 11 (14) 49 (64) 17 (22) 0.18
Sleeping 28.7 (30.2) 18 (22) 45 (56) 17 (21) 28.7 (31.3) 12 (16) 40 (53) 23 (31) 0.14
Diarrhoea 3.7 (14.9) 3 (4) 62 (78) 14 (18) 4.4 (13.2) 5 (7) 47 (64) 22 (30) 0.22
Dyspnoea 26.5 (18.1) 11 (14) 55 (68) 15 (19) 27.1 (19.9) 11 (14) 51 (67) 14 (18) 0.95
Cough 37.3 (24.2) 14 (17) 50 (62) 17 (21) 38.7 (26.8) 27 (36) 40 (53) 9 (12) 0.007
Haemoptysis 5.0 (13.7) 3 (4) 76 (95) 1 (1) 3.3 (10.1) 4 (5) 69 (92) 2 (3) 0.95
Sore mouth 8.9 (18.2) 6 (7) 63 (78) 12 (15) 6.3 (15.5) 4 (5) 53 (71) 18 (24) 0.16
Swallowing 8.3 (17.3) 11 (14) 63 (78) 7 (9) 7 (17.3) 7 (10) 57 (77) 10 (14) 0.27
Neuropathy 20.5 (27.2) 9 (12) 56 (72) 13 (17) 19.7 (28.1) 10 (13) 53 (70) 13 (17) 0.95
Hair loss 14.2 (25.5) 5 (6) 30 (37) 46 (57) 13.3 (23.2) 8 (11) 54 (72) 13 (17) o0.0001
Pain chest 17.2 (23.4) 12 (15) 62 (77) 7 (9) 16.3 (25.3) 10 (14) 53 (73) 10 (14) 0.52
Pain shoulder 26.1 (29.3) 17 (21) 50 (62) 14 (17) 25.0 (28.6) 20 (27) 47 (63) 8 (11) 0.24
Pain elsewhere 22.6 (26.4) 23 (29) 41 (52) 15 (19) 21.5 (27.5) 17 (23) 52 (70) 5 (7) 0.64
Bold values are statistically significant.
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land hair loss; nonneutropenic infections were more frequent with
weekly docetaxel. At least one grade 3–4 toxicity was observed in
38 and 20% (P¼0.006), 25 and 6% (P¼0.0003) 20 and 16%
(P¼0.48) of patients as far as any type, haematological or
nonhaematological toxicity are considered in the 3-week and
weekly arms, respectively. Overall six patients (three in each arm)
died during treatment without evidence of disease progression: in
the 3-week arm, one (with previous ischaemic hearth disease) died
because of atrial fibrillation and subsequent heart failure, one died
for septic shock following a broncopneumonitis associated with
neutropenia and one died suddenly, with cough and thoracic pain;
in the weekly arm, one died with pulmonary thromboembolism
and two died for cardiac arrest without other signs of toxicity.
DISCUSSION
Second-line chemotherapy with docetaxel 75mgm
 2 once every 3
weeks has become a standard of treatment for advanced NSCLC
patients thanks to two randomised phase III trials (Fossella et al,
2000; Shepherd et al, 2000). In the first one, chemotherapy with
docetaxel 100 or 75mgm
 2 was compared to best supportive care,
and significantly prolonged median survival (7.0 vs 4.6 months).
The 100mgm
 2 dose was associated with a high toxic death rate,
while, at the 75mgm
 2 dose, benefits outweighed risks (Shepherd
et al, 2000). In the second trial, docetaxel 100 and 75mgm
 2 were
each compared with a control regimen of vinorelbine or
ifosfamide. At the 75mgm
 2 dose, median time to progression
was slightly longer (8.5 vs 7.9 months) and a significantly higher
proportion of patients were progression-free (17 vs 8%) and alive
(32 vs 19%) at 1 year, as compared with the control arm (Fossella
et al, 2000). However, myelosuppression associated with docetaxel
in both the previous trials was extremely frequent and severe. On
these basis, and following a phase II study suggesting weekly
docetaxel be less toxic but not less active than the standard
schedule (Lilenbaum et al, 2001), we performed the DISTAL-1
randomised phase III trial to compare the effects of these two
schedules primarily on QOL, and secondarily on overall survival,
response rate and toxicity.
In the present study, QoL pattern generally favoured the weekly
arm. Advantages in this arm were statistically significant for hair
loss, pain and cough. The latter two items clearly show that weekly
docetaxel effectively palliated the most frequent symptoms of
advanced NSCLC. Diarrhoea was the only QoL item that was
Better
Cognitive functioning
Role functioning
Social functioning
Emotional functioning
Physical functioning
Fatigue
Nausea / vomiting
Pain
Sleeping disturbance
Constipation
Diarrhoea
Financial
Loss of appetite
Swallowing
Dyspnoea
Neuropathy
Cough
Hemoptysis
Sore mouth
Pain in shoulder
Pain elsewhere
Hair loss
Pain in chest
−10 01 02 0
Questionnaire no. 2 Questionnaire no. 3
∗
∗
∗
∗
Global QoL
30 −10 01 02 0 3 0
Mean change from questionnaire no. 1 (baseline)
Worse Better Worse
Figure 3 Mean change in EORTC quality of life scores at 3 weeks and at 6 weeks from baseline. Dotted bars represent weekly docetaxel, black bars
represent standard 3-weekly docetaxel. Asterisks indicate statistically significant differences.
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lunfavourable with the weekly treatment. Nonetheless, although
several advantages in toxicity and specific QoL items, no difference
in global QoL, measured by questions 29 and 30 of the EORTC C-
30 questionnaire, was found. This observation, that we already
reported in another trial (Gridelli et al, 2003), opens questions
regarding sensitivity of the different QoL items, either general or
specific, during the course of the disease.
Regardless the great consideration the oncological community
has for QoL as a substantial hard end point (American Society of
Clinical Oncology, 1996), effects on survival of different treatment
options are also crucial for therapeutic decisions. The present
study, powered to rule out a 0.67 hazard ratio of death with the
weekly schedule, suggests survival be very similar with the two
compared schedules (HR of death 1.04), although, of course,
interpretation of data in terms of equivalence (Jones et al, 1996) is
not allowed.
Considering toxicity, our results, consistent with previous ones
in phase II (Lilenbaum et al, 2001), point out that the weekly
schedule is less toxic than the standard 3-weekly one. This holds
true for anaemia, leucopenia, neutropenia, febrile neutropenia and
alopecia. This information may be of great value, considering the
palliative aim of treatment of patients with advanced NSCLC.
Differences found in the incidence and severity of neutropenia and
febrile neutropenia are also important for a possible reduction of
the cost of supportive care (i.v. antibiotics, CSFs administration,
hospitalisations) required in such cases. Similar results have been
recently reported in a randomised phase II trial of weekly
(40mgm
 2 for 6 weeks with 2 weeks of rest) and standard
(100mgm
 2 every 3 weeks) docetaxel in metastatic breast cancer
(Tabernero et al, 2004). In this study, indeed, overall 49% in the
weekly arm vs 76% in the 3-weekly arm experienced grade 3–4
adverse events and differences appeared substantial for neutrope-
nia with or without fever, neurotoxicity and stomatitis. All efficacy
parameters (response rate, time to progression and survival) were
similar in the two groups. Further, similar results have also been
reported with paclitaxel, which appears to be even more effective
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lin breast cancer when given weekly instead of 3-weekly (Green
et al, 2002a,b).
Recently, pemetrexed was found equivalent to 3-week docetaxel,
in a large phase III study involving 571 patients in second-line
treatment for advanced NSCLC (Hanna et al, 2004). In that study,
survival, response rate and QOL results were superimposable, but
pemetrexed was less toxic particularly for haematological toxicity
and related hospitalisations and complications. Based on our
results, weekly docetaxel could be at least as interesting as
pemetrexed and worth of direct comparison with it.
In conclusion, we suggest that the weekly schedule could be
preferred for patients candidate to receive docetaxel as second-line
chemotherapy for an advanced NSCLC, because of a better safety
profile, some positive effects on QoL and no evidence of strikingly
different effect on survival as compared to the 3-week schedule.
As for future perspectives, open questions relate to how to
include new drugs, like pemetrexed (Hanna et al, 2004), erlotinib
(Shepherd et al, 2004) or gefitinib (Fukuoka et al, 2003), and to
whether polychemotherapy can improve the results of single agent
treatment. The DISTAL-2 trial will compare weekly docetaxel with
combinations of weekly docetaxel plus capecitabine (Nadella et al,
2002), vinorelbine (Miller et al, 2000; Leu et al, 2001) and
gemcitabine (Kosmas et al, 2001; Spiridonidis et al, 2001); for this
trial the DISTAL Investigators agreed to apply a slightly modified
schedule of docetaxel (i.e. treatment for 3 consecutive weeks
followed by 1 week of rest) that should be equivalent to the one
studied in the DISTAL-1 trial, but more easy to combine with other
cytotoxic agents.
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